Throughout the last three months, 12 analysts have evaluated BioNTech (NASDAQ:BNTX), offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts have recently evaluated BioNTech and provided 12-month price targets. The average target is $129.33, accompanied by a high estimate of $171.00 and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 8.42% from the previous average price target of $119.29.

Deciphering Analyst Ratings: An...